An objective method for assessing adherence to prophylaxis in adults with severe haemophilia

Haemophilia

Volumn 20, Issue 1, 2014, Pages 39-43

  Ho, S ^a   Gue, D ^b   Mcintosh, K ^b   Bucevska, M ^b   Yang, M ^b   Jackson, S ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Provincial Bleeding Disorders Program Adult Division   (Canada)

Author keywords

Adherence; Factor replacement; Haemophilia; Infusion log; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; HEMATOLOGIC AGENT; PROPHYLACTIC FACTOR; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTHROPATHY; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTINUOUS INFUSION; DISEASE SEVERITY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFUSION; MEDICATION COMPLIANCE; MIDDLE AGED; MIXED INFECTION; NURSING ASSESSMENT; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; SCORING SYSTEM; SELF REPORT; TREATMENT DURATION; VISUAL ANALOG SCALE; YOUNG ADULT;

ADHERENCE; FACTOR REPLACEMENT; HAEMOPHILIA; INFUSION LOG; PROPHYLAXIS;

ADOLESCENT; ADULT; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PREMEDICATION; YOUNG ADULT;

EID: 84890857576     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12235     Document Type: Article

References (14)

1. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1-4.
2. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
3. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
4. Shapiro A, Gruppo R, Pabinger I et al. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther 2009; 9: 273-83.
5. Du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13: 493-501.
6. De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14: 931-8.
7. Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247-55.
8. Package Insert. ADVATE [Antihemophilic factor (recombinant), plasma/albumin-free method] Prescribing Information. Westlake Village: Baxter Healthcare Corporation, 2010.
9. World Health Organization Report. Adherence to long-term therapies: evidence for action. Available at http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf, 2003. Accessed 23 July 23.
10. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
11. Chan AKC, Decker K, Warner M. Adherence with haemophilia treatments: a survey of haemophilia healthcare professionals in Canada. Haemophilia 2011; 17: 816-7.
12. Davies MJ, Gagliardino JJ, Gray LF, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med 2013; 30: 512-24.
13. Porter JB, Evangeli M, El-Beshlawy A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol 2011; 94: 453-60.
14. Cleary J, McGroarty F, Singleton E, Bird R. PO-TU-109: using a smartphone app and medication bar-coding for treatment recording to improve patient safety and reduce treatment costs [abstract]. Haemophilia 2012; 18: 59.